CARDAMYST™ (etripamil) Nasal Spray: A New Treatment Option for Paroxysmal Supraventricular Tachycardia (PSVT)
On March 27, 2025, the US Food and Drug Administration (FDA) announced the approval of CARDAMYST™ (etripamil tartrate) nasal spray for the treatment of symptomatic Paroxysmal Supraventricular Tachycardia (PSVT) in adults. This marks a significant milestone in the management of this common heart rhythm disorder.
What is Paroxysmal Supraventricular Tachycardia (PSVT)?
PSVT is a type of heart rhythm disorder characterized by rapid, irregular heartbeats originating above the ventricles in the atria. These episodes can last from a few seconds to several hours and may cause symptoms such as palpitations, dizziness, shortness of breath, and fatigue. PSVT can lead to reduced cardiac output, which may result in fainting or even cardiac arrest if left untreated.
How does CARDAMYST™ (etripamil) nasal spray work?
CARDAMYST™ is a novel treatment option for PSVT that utilizes a unique delivery system: a nasal spray. Etripamil, the active ingredient in the spray, is a calcium channel blocker that works by slowing down the heart rate and reducing the likelihood of PSVT episodes. When sprayed into the nose, etripamil is absorbed through the mucosal lining of the nasal cavity and enters the bloodstream, bypassing the first-pass metabolism in the liver, allowing for faster onset of action.
Clinical Trials and Efficacy
The approval of CARDAMYST™ was based on the results of two randomized, double-blind, placebo-controlled studies involving a total of 441 patients with symptomatic PSVT. The studies demonstrated that etripamil nasal spray significantly reduced the number of PSVT episodes per week compared to placebo. The most common adverse events reported were headache, rhinitis, and nasal burning, which were generally mild to moderate in severity.
What does this mean for me?
If you are one of the millions of people living with PSVT, the approval of CARDAMYST™ may provide a new, convenient, and effective treatment option for managing your condition. The nasal spray offers several advantages over traditional treatment methods, such as a faster onset of action and improved patient compliance due to its non-invasive nature. However, it is essential to consult with your healthcare provider to determine if CARDAMYST™ is the right treatment for you based on your individual medical history and current medications.
What does this mean for the world?
The approval of CARDAMYST™ represents a significant advancement in the field of cardiology and the management of heart rhythm disorders. This new treatment option offers several benefits, including a non-invasive delivery system, faster onset of action, and improved patient compliance. Moreover, the availability of a new treatment for PSVT may lead to a reduction in healthcare costs associated with hospitalizations and emergency room visits. Furthermore, the success of CARDAMYST™ may pave the way for the development of similar nasal spray treatments for other cardiac conditions.
Conclusion
The approval of CARDAMYST™ (etripamil tartrate) nasal spray by the FDA marks a significant milestone in the treatment of Paroxysmal Supraventricular Tachycardia (PSVT). This novel treatment option offers several advantages over traditional methods, including a non-invasive delivery system, faster onset of action, and improved patient compliance. For individuals living with PSVT, this new treatment may provide a more convenient and effective way to manage their condition. Additionally, the success of CARDAMYST™ may lead to the development of similar treatments for other cardiac conditions, ultimately improving the quality of life for millions of people worldwide. Always consult your healthcare provider for medical advice and to determine if CARDAMYST™ is the right treatment option for you.
- CARDAMYST™ (etripamil tartrate) nasal spray approved by FDA for PSVT
- Non-invasive delivery system, faster onset of action, and improved patient compliance
- Significant advancement in the field of cardiology and heart rhythm disorders
- May lead to a reduction in healthcare costs associated with hospitalizations and emergency room visits
